Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer

Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer

Savolitinib, a small-molecule inhibitor of the receptor tyrosine kinase mesenchymal-epithelial transition (MET) factor, was approved for the treatment of non-small cell lung cancer (NSCLC) by the China National Medical Products Administration in June 2021. Its safety for NSCLC treatment has been con...

Full description

Bibliographic Details
Main Authors: Ye Xiong, Qing Cao, Yongzheng Guo, Xiang Liu, Xueling Zhu, Bohao Dai, Biao Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Pharmacology
Subjects:
shock
adverse drug rection
targeted therapy
savolitinib
HIV-1
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1089184/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1089184/full

Similar Items